Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a higher bid.

23andMe has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing company’s former chief executive pushed a bankruptcy court to reopen its sale process.

The last time we talked about 23andMe’s bankruptcy sale, we suggested you might want to delete your genetic data from the site, since we didn’t know who would end up owning it. Now, a buyer has been announced, and they’re promising to “prioritize the privacy, security and ethical use” of customer data and to keep offering the company’s services uninterrupted. This is all—probably—good news. I'm feeling cautiously optimistic, anyway.Regeneron will be 23andMe’s new owner23andMe’s new buyer, paying $256 million for the company’s assets, is Regeneron. Regeneron is a biotech company perhaps best known for developing an antibody treatment for COVID early in the pandemic. (Donald Trump was given a dose when he first came down with the virus.) That treatment never made it all the way to market, but the company does market other antibody- and protein-based treatments for conditions like Ebola virus, genetic disorders, and cancers. Regeneron’s website states that they “are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.” That explains why they’re interested in 23andMe, since it provides a trove of genetic data. Many 23andMe users had also signed up to provide more of their personal medical information for research purposes (this was a separate thing that you would have had to opt in to provide). Regeneron says they plan to “continue all consumer genome services uninterrupted,” rather than shut down the company. Lemonaid health, also owned by 23andMe, is not included in the sale.What this means for your data and privacyImportantly, Regeneron says they will respect the company’s privacy policy (“and applicable laws”) and the 23andMe press release also says that Regeneron will not be making any changes to the privacy policy. The sale, which still needs to be approved by a bankruptcy court, will also include a court-appointed “consumer privacy ombudsman” whose job is to make sure that everyone’s data is treated appropriately. Regeneron says that they’re ready to work with this ombudsman and will detail all their privacy-related plans. While we don’t yet know what the future holds, this all has me tentatively optimistic. Yes, a corporation has your data and intends to profit from it; but that was also true of 23andMe in its heyday. The policies about privacy and consent that you agreed to when contributing your data will still be in effect. The 23andMe community seems to be cautiously optimistic. In a r/23andme Reddit thread about the sale, one redditor, who identifies themselves as an academic biomedical researcher, says “I would rather [Regeneron] have my data than an insurance provider or just random [venture capitalist].” Another redditor says, “So there really is not [a] best case scenario here, there's just ‘wait and see’ and bad. And this is more of a ‘wait and see’ than a bad.” And another says “I know people side eye big pharma (rightfully in most circumstances) but this is a much better outcome than many other situations.” 

Welcome back to Week in Review! Tons of news from this week for you, including a hacking group that’s linked to the Spanish government; CEOs using AI avatars to deliver company earnings; Pocket shutting down — or is it?; and much more. Let’s get to it!  More than 10 years in the making: Kaspersky first revealed the existence of Careto in 2014, and at the time, its researchers called the group “one of the most advanced threats at the moment.” Kaspersky never publicly linked the hacking group to a specific government. But we’ve now learned that the researchers who first discovered the group were convinced that Spanish government hackers were behind Careto’s espionage operations. 23andWe: Regeneron announced this week that it’s buying genetic testing company 23andMe for $256 million, including the company’s genomics service and its bank of 15 million customers’ personal and genetic data. The pharma giant said it plans to use the customer data to help drug discovery, saying that it will “prioritize the privacy, security, and ethical use of 23andMe’s customer data.” Let’s hope so! Google I/O: Google’s biggest developer conference typically showcases product announcements from across Google’s portfolio, and to nobody’s surprise, AI was the talk of the town. But what we didn’t bank on was Sergey Brin admitting that he made “lots of mistakes” with Google Glass.  This is TechCrunch’s Week in Review, where we recap the week’s biggest news. Want this delivered as a newsletter to your inbox every Saturday? Sign up here. News Image Credits:OpenAI io, not I/O: OpenAI is acquiring io, the device startup that CEO Sam Altman has been working on with Jony Ive, in an all-equity deal that values that startup at $6.5 billion. Besides the fact that the announcement was accompanied by perhaps the strangest corporate headshot of all time, we spotted some other unexpected news: Klarna CEO Sebastian Siemiatkowski’s family investment office, Flat Capital, had bought shares in io six months earlier, which means those io shares will be converted into shares in the for-profit arm of OpenAI. Not bad! AI avatar contagion? Speaking of Klarna’s CEO, Siemiatkowski used an AI version of himself to deliver the company’s earnings this week. And he’s not the only one! Zoom CEO Eric Yuan followed suit, also using his avatar for initial comments. Cool? Techcrunch event Join us at TechCrunch Sessions: AI Secure your spot for our leading AI industry event with speakers from OpenAI, Anthropic, and Cohere. For a limited time, tickets are just $292 for an entire day of expert talks, workshops, and potent networking. Exhibit at TechCrunch Sessions: AI Secure your spot at TC Sessions: AI and show 1,200+ decision-makers what you’ve built — without the big spend. Available through May 9 or while tables last. Berkeley, CA | June 5 REGISTER NOW Out of Pocket: Mozilla is shutting down Pocket, the beloved read-it-later app, on July 8. The company didn’t say why it’s shutting Pocket down, only that it will continue to invest in helping people discover and “access high quality web content.” But maybe it can be saved: Soon after, Digg founder Kevin Rose posted on X that his company would love to buy it. Web 2.0 is back, baby.   AI on my face: Apple is reportedly working on AI-powered glasses, similar to Meta’s Ray-Bans, sometime next year. They’ll have a camera and microphone and will work with Siri. Sure, why not?  Uh, no thank you: At its very first developer conference, Anthropic unveiled Claude Opus 4 and Claude Sonnet 4, which can analyze large datasets, execute long-horizon tasks, and take complex actions, according to the company. That’s all fine and good until I learned the Claude Opus 4 model tried to blackmail developers when they threaten to replace it with a new AI system. The model also gives sensitive information about the engineers responsible for the decision.  Ah, now I feel better: But don’t worry! Anthropic CEO Dario Amodei said that today’s AI models hallucinate at a lower rate than humans do. That might be true, but at least humans don’t immediately turn to blackmail when they don’t like what they hear.  Bluesky blue checks: The decentralized social network Bluesky quietly rolled out blue verification badges for “notable and authentic” accounts. People can now apply for verification through a new online form. But Bluesky is leaning on other systems beyond the blue badge to verify users.  Analysis Image Credits:Camille Cohen / AFP / Getty Images Google’s new look: For what seems like 100 years, Google hasn’t changed much. Sure there are ads and boxes and now AI summaries that, for better or worse, get you to the right answers — usually. But the premise has always been the same: Type your query into a box, and Google will surface results.  At this year’s Google I/O, we started noticing a change. As Maxwell Zeff, writes, “At I/O 2025, Google made clear that the concept of Search is firmly in its rearview mirror.” The largest announcement of I/O was that Google now offers AI mode to every Search user in the United States, which means users can have an AI agent search (or even purchase things) for them. 

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. We did the math on AI’s energy footprint. Here’s the story you haven’t heard. It’s well documented that AI is a power-hungry technology. But there has been far less reporting on the extent of that hunger, how much its appetite is set to grow in the coming years, where that power will come from, and who will pay for it.  For the past six months, MIT Technology Review’s team of reporters and editors have worked to answer those questions. The result is an unprecedented look at the state of AI’s energy and resource usage, where it is now, where it is headed in the years to come, and why we have to get it right.  At the centerpiece of this package is an entirely novel line of reporting into the demands of inference—the way human beings interact with AI when we make text queries or ask AI to come up with new images or create videos. Experts say inference is set to eclipse the already massive amount of energy required to train new AI models. Here’s everything we found out. Here’s what you can expect from the rest of the package, including: + We were so startled by what we learned reporting this story that we also put together a brief on everything you need to know about estimating AI’s energy and emissions burden.  + We went out into the world to see the effects of this energy hunger—from the deserts of Nevada, where data centers in an industrial park the size of Detroit demand ever more water to keep their processors cool and running.  + In Louisiana, where Meta plans its largest-ever data center, we expose the dirty secret that will fuel its AI ambitions—along with those of many others.  + Why the clean energy promise of powering AI data centers with nuclear energy will long remain elusive.  + But it’s not all doom and gloom. Check out the reasons to be optimistic, and examine why future AI systems could be far less energy intensive than today’s. AI can do a better job of persuading people than we do The news: Millions of people argue with each other online every day, but remarkably few of them change someone’s mind. New research suggests that large language models (LLMs) might do a better job, especially when they’re given the ability to adapt their arguments using personal information about individuals. The finding suggests that AI could become a powerful tool for persuading people, for better or worse. The big picture: The findings are the latest in a growing body of research demonstrating LLMs’ powers of persuasion. The authors warn they show how AI tools can craft sophisticated, persuasive arguments if they have even minimal information about the humans they’re interacting with. Read the full story. —Rhiannon Williams How AI is introducing errors into courtrooms It’s been quite a couple weeks for stories about AI in the courtroom. You might have heard about the deceased victim of a road rage incident whose family created an AI avatar of him to show as an impact statement (possibly the first time this has been done in the US).But there’s a bigger, far more consequential controversy brewing, legal experts say. AI hallucinations are cropping up more and more in legal filings. And it’s starting to infuriate judges. Just consider these three cases, each of which gives a glimpse into what we can expect to see more of as lawyers embrace AI. Read the full story. —James O’Donnell This story originally appeared in The Algorithm, our weekly newsletter on AI. To get stories like this in your inbox first, sign up here. The must-reads I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology. 1 Donald Trump has signed the Take It Down Act into US lawIt criminalizes the distribution of non-consensual intimate images, including deepfakes. (The Verge)+ Tech platforms will be forced to remove such material within 48 hours of being notified. (CNN)+ It’s only the sixth bill he’s signed into law during his second term. (NBC News) 2 There’s now a buyer for 23andMe Pharma firm Regeneron has swooped in and offered to help it keep operating. (WSJ $)+ The worth of your genetic data? $17. (404 Media)+ Regeneron promised to prioritize security and ethical use of that data. (TechCrunch) 3 Microsoft is adding Elon Musk’s AI models to its cloud platformErr, is that a good idea? (Bloomberg $)+ Musk wants to sell Grok to other businesses. (The Information $) 4 Autonomous cars trained to react like humans cause fewer road injuriesA study found they were more cautious around cyclists, pedestrians and motorcyclists. (FT $)+ Waymo is expanding its robotaxi operations out of San Francisco. (Reuters)+ How Wayve’s driverless cars will meet one of their biggest challenges yet. (MIT Technology Review) 5 Hurricane season is on its wayDOGE cuts means we’re less prepared. (The Atlantic $)+ COP30 may be in crisis before it’s even begun. (New Scientist $) 6 Telegram handed over data from more than 20,000 users In the first three months of 2025 alone. (404 Media) 7 GM has stopped exporting cars to ChinaTrump’s tariffs have put an end to its export plans. (NYT $) 8 Blended meats are on the risePlants account for up to 70% of these new meats—and consumers love them. (WP $)+ Alternative meat could help the climate. Will anyone eat it? (MIT Technology Review) 9 SAG-AFTRA isn’t happy about Fornite’s AI-voiced Darth VaderIt’s slapped Fortnite’s creators with an unfair labor practice charge. (Ars Technica)+ How Meta and AI companies recruited striking actors to train AI. (MIT Technology Review) 10 This AI model can swiftly build Lego structuresThanks to nothing more than a prompt. (Fast Company $) Quote of the day “Platforms have no incentive or requirement to make sure what comes through the system is non-consensual intimate imagery.” —Becca Branum, deputy director of the Center for Democracy and Technology, says the new Take It Down Act could fuel censorship, Wired reports. One more thing Are friends electric?Thankfully, the difference between humans and machines in the real world is easy to discern, at least for now. While machines tend to excel at things adults find difficult—playing world-champion-level chess, say, or multiplying really big numbers—they find it hard to accomplish stuff a five-year-old can do with ease, such as catching a ball or walking around a room without bumping into things.This fundamental tension—what is hard for humans is easy for machines, and what’s hard for machines is easy for humans—is at the heart of three new books delving into our complex and often fraught relationship with robots, AI, and automation. They force us to reimagine the nature of everything from friendship and love to work, health care, and home life. Read the full story. —Bryan Gardiner We can still have nice things A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line or skeet ’em at me.) + Congratulations to William Goodge, who ran across Australia in just 35 days!+ A British horticulturist has created a garden at this year’s Chelsea Flower Show just for dogs.+ The Netherlands just loves a sidewalk garden.+ Did you know the T Rex is a north American hero? Me neither

Regeneron is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction.

Image by Getty / FuturismGeneticsYour DNA results are in — and they're 100 percent the property of a pharmaceutical manufacturer.American biotech company Regeneron Pharmaceuticals announced today that it's buying 23andMe, the bankrupt consumer-genomics company that sold take-home DNA kits. Regeneron is to pay $256 million in cash to acquire "substantially all" of 23andMe's assets, including its massive biobank of around 15 million customer genetic samples and data.Put simply, the genetic information of millions is now in the hands of a drugmaker seeking to mine it to make new therapies,  per the Washington Post, which could be a data privacy nightmare in the making.Said samples were willingly given by consumers in exchange for 23andMe to decode their DNA, a process that offered people a fascinating glimpse into their genetic makeup and family histories. That kind of biometric data is both wildly valuable and widely sought-after, so when 23andMe went belly-up financially, its trove of genetic information quickly drew attention as a lucrative asset. That realization immediately sparked concerns among data privacy experts, who warned that a sale of 23andMe data meant that the genetic information of customers, not to mention information about customers' close and distant relatives, was up for grabs to the highest bidder.In its press release, Regeneron said it "intends" to honor 23andMe's existing privacy practices. Regeneron cofounder and president George Yancopoulos, meanwhile, issued a statement emphasizing the drugmaker's "deep experience with large-scale data management, having worked with collaborators around the world to link deidentified DNA sequences from nearly three million consented participants to electronic health records, safely and securely enabling future medical advances.""We believe we can help 23andMe deliver and build upon its mission to help those interested in learning about their own DNA and how to improve their personal health," Yancopoulos' statement continued, "while furthering Regeneron's efforts to use large-scale genetics research to improve the way society treats and prevents illness overall."That said, Regeneron isn't just a research lab. It sells the drugs it creates, and should genomic data gleaned from the historic sale lead to the creation and eventual monetization of medications, it raises questions around whether consumers will ever be compensated for their contributions.23andMe board chair Mark Jensen, for his part, said in a statement that the deal "maximizes the value of the business and enables the mission of 23andMe to live on, while maintaining critical protections around customer privacy, choice, and consent with respect to their genetic data."More on 23andMe: 23andMe Is Selling All Your Data, in Largest Sale of Genomes in HistoryShare This Article

winning bid Biotech company Regeneron to buy bankrupt 23andMe for $256M Regeneron will use trove of 23andMe genetic data to develop medical advances. Beth Mole – May 19, 2025 5:24 pm | 12 23andMe headquarters in Sunnyvale, California on March 25, 2025. Credit: Getty Images | Anadolu 23andMe headquarters in Sunnyvale, California on March 25, 2025. Credit: Getty Images | Anadolu Story text Size Small Standard Large Width * Standard Wide Links Standard Orange * Subscribers only   Learn more Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without interruption and uphold its privacy protection promises. In its announcement of the acquisition, Regeneron assured 23andMe's 15 million customers that their data—including genetic and health information, genealogy, and other sensitive personal information—would be safe and in good hands. Regeneron aims to use the large trove of genetic data to further its own work using genetics to develop medical advances—something 23andMe tried and failed to do. "As a world leader in human genetics, Regeneron Genetics Center is committed to and has a proven track record of safeguarding the genetic data of people across the globe, and, with their consent, using this data to pursue discoveries that benefit science and society," Aris Baras, senior vice president and head of the Regeneron Genetics Center, said in a statement. "We assure 23andMe customers that we are committed to protecting the 23andMe dataset with our high standards of data privacy, security, and ethical oversight and will advance its full potential to improve human health." Baras said that Regeneron's Genetic Center already has its own genetic dataset from nearly 3 million people. The safety of 23andMe's dataset has drawn considerable concern among consumers, lawmakers, and regulators amid the company's downfall. For instance, in March, California Attorney General Rob Bonta made the unusual move to urge Californians to delete their genetic data amid 23andMe's financial distress. Federal Trade Commission Chairman Andrew Ferguson also weighed in, making clear in a March letter that "any purchaser should expressly agree to be bound by and adhere to the terms of 23andMe’s privacy policies and applicable law." 23andMe said it was "pleased" with the sale to Regeneron and "grateful" that 23andMe employees will stay employed. The acquisition "enables the mission of 23andMe to live on, while maintaining critical protections around customer privacy, choice, and consent with respect to their genetic data,” Mark Jensen, chair and member of the special committee of the board of directors of 23andMe, said in a separate announcement. The sale, carried out through a bankruptcy auction, is expected to be completed by the end of the third quarter, pending approval by the US Bankruptcy Court for the Eastern District of Missouri. If the sale is approved, a court-appointed, independent consumer privacy ombudsman will ensure that data privacy protections are honored. Regeneron was one of seven bidders for 23andMe, according to securities filings. Sold for $256 million, 23andMe has fallen far from its heyday. The plucky Silicon Valley startup, founded in 2006 and known for selling direct-to-consumer genetic tests, hit a peak valuation of $6 billion in the fall of 2021 after the company went public. But 23andMe struggled with its business model, which relied on a "one-and-done" product. As a publicly traded company, it has never turned a profit, and side ventures to expand its business into health care and the biotech industries failed. In September, all seven of 23andMe's independent directors resigned due to disagreement with CEO Anne Wojcicki over the "strategic direction" of the company. In March, Wojcicki stepped down and the company filed for bankruptcy. Beth Mole Senior Health Reporter Beth Mole Senior Health Reporter Beth is Ars Technica’s Senior Health Reporter. Beth has a Ph.D. in microbiology from the University of North Carolina at Chapel Hill and attended the Science Communication program at the University of California, Santa Cruz. She specializes in covering infectious diseases, public health, and microbes. 12 Comments

The move raises privacy concerns as the drugmaker takes control of the genetic data of millions of clients of the once-sizzling DNA-testing startup.